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Stroke is a leading cause of morbidity and mortality in developed countries, with a significant proportion of stroke survivors requiring institutional care and/or remaining 
permanently disabled [1]. Finding adequate treatments to promote patient’s recovery is therefore a priority task, requiring the elucidation of the molecular pathways influencing 
brain recovery. Family and animal studies suggest that stroke recovery is influenced by genetic factors [2] but, except for the apolipoprotein E (APOE) gene [3, 4], few 
candidate genes have been tested for association with stroke outcome and no genome-wide association study (GWAS) has been reported.  
Performing GWAS in DNA pooled samples is a cost-effective alternative to traditional GWAS and has successfully been used to identify genes associated with several traits [6-
8]. With this technique, DNA from different individuals are pooled together and the SNP allele frequencies from each DNA pool are estimated using single nucleotide 
polymorphism (SNP) microarrays, a strategy known as allelotyping. SNPs associated with the phenotype in an initial phase can then be confirmed by individual genotyping.  
This study describes a pilot GWAS to identify genetic factors contributing to patient’s outcome, using a DNA pooling design. 
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A genome-wide association study using a DNA pooling 
strategy identifies BBS9 and GLIS3 as novel loci 
influencing patient’s outcome after stroke 
INTRODUCTION 
METHODS 
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 12 SNPs were excluded due to failure of quality control measures; 88 SNPs were 
analyzed. 36 SNPs (approximately 41%) were validated, showing significant differences 
between patients with extremely good and extremely poor outcome at three months 
(1.7x10-4<P<0.049). Of these, 13 SNPs had p-values below 0.005.  
SNP selection strategies were evaluated by comparing the percentage of true-
positive/validated markers obtained for each strategy. Selecting SNPs according to 
allele frequency difference between groups and selecting consecutive SNPs showed 
better performances, with 56.8% and 57.1%, respectively, of SNP validation. Choosing 
SNPs according to the t-test p-values showed a poor performance, with a SNP 
validation of 20.7%. Selecting SNPs within the same gene showed an intermediate 
performance, as 28.6% of SNPs were validated. 
 15 out of the 36 validated SNPs were associated with stroke outcome (4.3x10-
4<uncorrectedP<0.047) in a larger sample of 230 patients including the whole range of mRS 
scores (Table 1).  
Six SNPs remained associated with stroke outcome after adjusting for stroke severity 
parameters (0.002<uncorrectedP<0.039) (Table 1). Two of these SNPs, rs10273634 and 
rs10974334, are located within the Bardet-Biedl syndrome 9 (BBS9) and GLIS family 
zinc finger 3 (GLIS3) genes. rs290916 is located downstream from a novel processed 
transcript (RP11-428L9.1-001), for which there is little information, and the other three 
SNPs are located in intergenic regions and far from other known loci.  
 In addition, we found a GLIS3 haplotype (T-A-G, rs7024250-rs1000128-rs10974334) 
significantly associated with stroke outcome (uncorrectedP=0.004, false discovery rate 
[FDR] q=0.024).  
Our preliminary results highlight two unexpected genes, BBS9 and GLIS3. Additional 
studies are required to validate this hypothesis and to understand their connection to 
stroke-induced disability and/or stroke recovery processes. Association analyses will be 
conducted with haplotype tagging SNPs to fully cover the genetic variability within these 
genes, and the results will need to be replicated in independent population samples, which 
are currently being recruited by several research groups.  
BBS9 encodes different isoforms of the PTHB1 protein, which are expressed in a variety 
of tissues, including the brain [11]. Mutations in this gene were identified in patients with 
Bardet-Biedl syndrome (BBS) (MIM ID: 209900). Obesity is one of the major clinical 
manifestations of BBS. Interestingly, it was observed that mice maintained in dietary energy 
restriction had smaller infarct volumes and less neurological impairment after stroke, which 
suggests that excessive energy intake or obesity can negatively influence stroke outcome 
[12]. 
 GLIS3 encodes different isoforms of the zinc finger protein GLIS3, a transcription factor 
that can act as a transcriptional activator and repressor [13]. This protein is expressed in 
the brain, among other tissues [13]. Polymorphisms within GLIS3 have been associated 
with type 1 diabetes [14], and with glycemic traits and type 2 diabetes [15]; and it was 
observed that diabetes is associated with severe disability after stroke [16].   
 Further studies are needed to investigate the role of the new processed transcript RP11-
428L9.1-001 and of the three intergenic SNPs (which may be influencing the expression 
levels of distantly located genes), and their potential relation to stroke outcome. 
DISCUSSION & CONCLUSIONS 
This work was conducted in three stages:  
1) Pooling-based association analysis 
A – Pool construction and allelotyping (estimation of SNP allele 
frequencies) in each pool, using genotyping arrays 
Pooling-based association analysis of two pools of patients 
classified in the extremes of a clinical outcome assessment 
instrument, the modified Rankin Scale (mRS). A pool of 87 
patients with very good outcome (mRS=0 – no disability 
symptoms) was constructed and compared with a pool of 100 
patients with very poor outcome (mRS≥3 – moderate to severe 
disability and death).  
Both pools were allelotyped using the 250K Affymetrix GeneChip® 
Mapping Assay – Nsp I that allows the analysis of 262,264 SNPs. 
RESULTS 
rs290916 10 9000349 68.5 79.2 4.3x10
-4
0.016 0.59 [0.39-0.92] 0.150
rs10974334 9 4092339 GLIS3 69.6 79.7 7.4x10
-4
0.038 0.64 [0.42-0.98] 0.155
rs2587163 4 186457029 SNX25 58.1 48.9 0.008 0.337
rs811322 3 139812552 FAIM 56.9 49.7 0.047 0.545
rs6590261 11 126806806 51.1 58.2 0.040 0.703
rs9293983 6 75618311 58.4 65.2 0.047 0.039 0.68 [0.46-0.98] 0.155
rs7131780 12 101722143 76.1 69.1 0.028 0.070
rs17627020 5 54203597 98.7 95.1 0.005 0.090
rs7664979 4 95544420 59.8 67.4 0.027 0.025 0.65 [0.45-0.95] 0.155
rs1295826 14 69186662 KIAA0247 86.2 91.3 0.026 0.078
rs1243659 14 20151347 80.0 87.1 0.005 0.008 0.50 [0.29-0.84] 0.109
rs17300340 1 178588341 ACBD6 81.3 86.7 0.037 0.169
rs7024250 9 3823480 GLIS3 91.0 89.6 0.020 0.485
rs10273634 7 33318154 BBS9 86.5 78.0 7.7x10
-4
0.002 2.21 [1.32-3.7] 0.057
rs3027232 17 7962790 ALOXE3 73.1 80.9 0.009 0.095
genepositionChrSNP ID FDR q
c
OR [95% CI]
b
adjustedP
b
unadjustedP
afreq Poor Recov 
(mRS>1)
freq Good Recov 
(mRS≤1)
Table 1 – Association results for the 15 SNPs associated with stroke outcome in the sample of 230 patients 
Odds Ratio (OR) >1 indicates increased probability of poor outcome at three months for the carriers of the minor allele.  
Chr – Chromosome, CI – confidence interval, FDR – false discovery rate, freq Good Recov – allele frequency (%) in patients with good outcome, freq Poor Recov – allele frequency (%) in patients with poor outcome. 
a P for the log-additive model. 
bOR [95% CI] and P for the log-additive genetic model after adjustment for significant covariates (history of hypertension, and occurrence of aphasia, paresis, altered consciousness and medical complications during 
hospitalization). 
cFDR qvalues. 
B – Selection of SNPs for individual genotyping 
Since there is no consensus on the best strategy for SNP selection, 
we chose the 100 most interesting markers based on four plausible 
strategies:  
a) SNPs with the largest allele frequency differences between the 
two pools of extremely good and poor outcome [9] (N=46),  
b) SNPs with the lowest Student’s t-test p-values for the differences 
between allele frequency estimates [7, 10] (N=34),  
c) SNPs that were clustered in 3 or more consecutive markers 
within 100kb from each other (N=14), and  
d) SNPs that were clustered in 3 or more consecutive markers 
within the same gene (according to RefSeq database) (N=15). 
For strategies c and d, SNPs were selected amongst the top 1000 
SNPs with larger allele frequency differences between pools and 
the top 1000 SNPs with lower t-test p-values.  
 
2) SNP validation 
Validation of the pooling strategy was performed by individual 
genotyping of the 100 most interesting SNPs, in the same 
individuals (87 patients with very good outcome and 100 patients 
with very poor outcome), using the Sequenom MassARRAY 
system.  
 
3) Association analysis in a larger sample 
Association analysis with stroke outcome of validated SNPs was 
carried out in a larger sample of stroke patients using a more 
clinically sensible mRS cut-off for good and poor recovery. 230 
patients with mRS≤1 (no symptoms/some symptoms but able to 
perform usual activities) were compared with 184 patients with 
mRS>1 (unable to perform usual activities to bedridden and death).  
